SA
AVDL

Sanctuary Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Sanctuary Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,873
Closed -$105K – 2421
2025
Q2 		$105K Sell
11,873
-9,409
-44% -$82.7K ﹤0.01% 2267
2025
Q1 		$167K Buy
21,282
+7,991
+60% +$66.9K ﹤0.01% 2069
2024
Q4 		$102K Buy
+13,291
New +$161K ﹤0.01% 2317

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Sanctuary Advisors's AVDL Position: Q3 2025 in Review

Sanctuary Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q3 2025, closing a stake of 11,873 shares — an estimated $105K sold.

Sanctuary Advisors first reported a position in AVDL in Q4 2024 and held it in 3 quarters. The position peaked at $167K in Q1 2025. 188 funds tracked by Wall St. Rank hold AVDL as of Q3 2025.

  • Sanctuary Advisors reported no remaining Avadel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sanctuary Advisors sold 11,873 Avadel Pharmaceuticals shares in Q3 2025, an estimated $105K.
  • Sanctuary Advisors first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Sanctuary Advisors's Avadel Pharmaceuticals position peaked at $167K in Q1 2025.
  • 188 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2025.

Based on Sanctuary Advisors's 13F filing for Q3 2025, filed 6 Jan 2026.